Harry Odabashian, MD
Cardiovascular Disease Physician in Albany, New York. This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers — including 24,795 in Cardiovascular Disease Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration — see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Harry Odabashian, MD reported a CMS MIPS final score of 76.7/100 — below the 83.1 national average — and filed 4,532 Medicare Part D claims in 2023.
- 76.7/100
- MIPS score · -6 vs avg
- 5K
- Part D claims, 2023
- 87%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
Harry Odabashian, MD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
77 21st percentile higher than 21% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Harry Odabashian, MD sits
This provider among cardiovascular disease physician peers
Across the 8,753 cardiovascular disease physician providers who report both Medicare Part D prescribing and a MIPS quality score, Harry Odabashian, MD writes more Part D claims than 70% of them and scores higher on MIPS quality than 25% — placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one cardiovascular disease physician peer from a representative sample of 60; the gold marker is Harry Odabashian, MD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Harry Odabashian, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Harry Odabashian, MD?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in New York
How Cardiovascular Disease Physician compares to other specialties among New York providers
Largest specialties in New York (% of in-state providers)
Cardiovascular Disease Physician ranks #43 among New York's specialties (0.4% of in-state providers)
Each bar is a specialty's share of the New York provider total, by primary NUCC taxonomy. The highlighted bar is Cardiovascular Disease Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance — MIPS
Harry Odabashian, MD's 2023 MIPS final score plotted against the Cardiovascular Disease Physician national average
- MIPS Final Score
- 76.7/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Cardiovascular Disease Physician) — 76.7/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Cardiovascular Disease Physician US NPIs
76.7/100 MIPS final score — 6.4 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Cardiovascular Disease Physician. Quality dim: 78. Cost dim: 61.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Harry Odabashian, MD appears in the CMS NPPES registry as a Cardiovascular Disease Physician provider holding MD credentials at 1365 WASHINGTON AVENUE, Albany, NY, 12206, with a listed phone of (518) 264-1800. NPI 1558369611 was issued on 07/12/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what Odabashian most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 4,532 prescription claims written by this provider, covering 452 Medicare beneficiaries and totaling roughly $752K in drug spend, split 13% brand-name and 87% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 76.7/100 for the 2023 performance year (Quality 78, Cost 61), compared with the national average of 83.1.
Cardiovascular Disease Physician is a mid-sized specialty nationwide, with 24,795 enrolled providers across 54 states and an average of 3,033 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1558369611 |
|---|---|
| Specialty | Cardiovascular Disease Physician |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 07/12/2005 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Harry Odabashian, MD's current license status, disciplinary history, and board certifications with the New York State Education Department, Office of the Professions in New York before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where Harry Odabashian, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Harry Odabashian, MD. Source: openpaymentsdata.cms.gov.
Total received
$21
Largest payer
Novartis Pharmaceuticals Corporation
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — New York NYSBPMC 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to Harry Odabashian, MD. To verify Harry Odabashian, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
13% brand-name claims vs 87% generic, on 4,532 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 12,583
- Total Day Supply
- 375,930
- Brand vs Generic
- 13% brand / 87% generic
- Brand Drug Cost
- $629K
- Generic Drug Cost
- $123K
- Antibiotic Claims
- 32
Patient Demographics
- Average Patient Age
- 77.4 years
- Avg HCC Risk Score
- 1.24
- Gender Split
- 40% female / 60% male
- Age Distribution
- <65: 11, 65-74: 149, 75-84: 219, 85+: 73
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Harry Odabashian, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Atorvastatin Calcium
Atorvastatin Calcium
514 claims
- Metoprolol Succinate
Metoprolol Succinate
480 claims
- Ezetimibe
Ezetimibe
368 claims
- Amlodipine Besylate
Amlodipine Besylate
348 claims
- Eliquis
Eliquis
308 claims
- Rosuvastatin Calcium
Rosuvastatin Calcium
209 claims
- Nifedipine Er 200
Nifedipine Er
200 claims
- Lisinopril 162
Lisinopril
162 claims
| Drug | Claims |
|---|---|
| Atorvastatin Calcium | 514 |
| Metoprolol Succinate | 480 |
| Ezetimibe | 368 |
| Amlodipine Besylate | 348 |
| Eliquis Apixaban | 308 |
| Rosuvastatin Calcium | 209 |
| Nifedipine Er Nifedipine | 200 |
| Lisinopril | 162 |
| Furosemide | 143 |
| Simvastatin | 139 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Cardiovascular Disease Physician Overview
How Harry Odabashian, MD fits within the Cardiovascular Disease Physician landscape nationally.
Harry Odabashian, MD's 4,532 claims are above the specialty average of 3,033.
Nearby Cardiovascular Disease Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Odabashian.
Compare Cardiovascular Disease Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry — providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the New York medical board — federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Cardiovascular Disease Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only — they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New York
Frequently Asked Questions
What is Harry Odabashian, MD's specialty? ▼
How much does Harry Odabashian, MD prescribe under Medicare Part D? ▼
What is Harry Odabashian, MD's Medicare quality score? ▼
Where is Harry Odabashian, MD located? ▼
What is Harry Odabashian, MD's NPI number? ▼
Does Harry Odabashian, MD prescribe more brand-name or generic drugs? ▼
How many Cardiovascular Disease Physician providers are there in the US? ▼
What drugs does Harry Odabashian, MD prescribe most often? ▼
Does Harry Odabashian, MD accept Medicare? ▼
How can I verify Harry Odabashian, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology